journal article·2018-11-12

Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage

Monika Kaurav, Jitender Madan, M. S. Sudheesh, Ravi Shankar Pandey

Publisher page

Abstract

Vaccines are a significant historical accomplishment in medical science due to its significance in saving millions of lives around the world with a manifold decline in disease burden and health expenditure. Since last decade, extensive efforts in vaccine design based on rational and experimental set up prompts the acknowledgement of several protective antigens; however, the utilization of those antigens as intense safe vaccines is still far beyond their discovery. The advancement of accomplished vaccines will need the combination of numerous strategies. In this way, the vaccine can be capable of provoking an abundant and effective immunization to compete against antigens with minimal/no adverse effects on recipients. First, stable and striking enough on the pharmaceutical point of view. Second, application of rational and realistic approaches to select an appropriate combination of adjuvant, antigen and delivery vehicle in the suitable formulation. Different vaccine adjuvants-delivery system combinations were discussed here elaborately, which are approved/licensed for human vaccines and are in various phases of clinical trials and pre-clinical trials. Challenges/limitations associated with vaccine designing and parameters to be considered, approaches to be applied, using available adjuvants are also detailed.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · vaccines and immunoinformatics approaches · Monoclonal and Polyclonal Antibodies Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya

Department of Pharmaceutics, Chandigarh College of Pharmacy

Faculty of Pharmacy, VNS Group of Institutions, Nathu Barkheda

Funding

UGC · University Grants Commission.

References (60)

Show source-provided references
1. 10.1038/nrd117610.1038/nrd1176 ↗
2. 10.2174/15672011179525619210.2174/156720111795256192 ↗
3. 10.2217/nnm.14.18710.2217/nnm.14.187 ↗
4. Mohan T, Verma P, Rao DN. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res. 2013;138:779–795.
5. 10.1007/s12038-009-0114-310.1007/s12038-009-0114-3 ↗
6. 10.1016/j.ijpharm.2008.04.03610.1016/j.ijpharm.2008.04.036 ↗
7. 10.1016/j.nano.2015.12.37210.1016/j.nano.2015.12.372 ↗
8. 10.1016/j.tips.2017.06.00210.1016/j.tips.2017.06.002 ↗
9. 10.1016/S0952-7915(00)00120-510.1016/S0952-7915(00)00120-5 ↗
10. 10.1016/j.jconrel.2013.01.01510.1016/j.jconrel.2013.01.015 ↗
11. 10.1517/17425247.2016.112198910.1517/17425247.2016.1121989 ↗
12. Kalam MA, Khan AA, Alshamsan A. Non-invasive administration of biodegradable nano-carrier vaccines. Am J Trans Res. 2017;9:15–35.
13. 10.1002/jps.2375710.1002/jps.23757 ↗
14. 10.1016/S0169-409X(98)00040-410.1016/S0169-409X(98)00040-4 ↗
15. 10.1586/14760584.6.3.40110.1586/14760584.6.3.401 ↗
16. 10.1080/14760584.2017.130644010.1080/14760584.2017.1306440 ↗
17. 10.1016/j.vaccine.2013.01.04210.1016/j.vaccine.2013.01.042 ↗
18. 10.1093/aje/kws19610.1093/aje/kws196 ↗
19. 10.1016/S1389-0344(01)00101-010.1016/S1389-0344(01)00101-0 ↗
20. 10.1016/j.ajps.2014.06.00210.1016/j.ajps.2014.06.002 ↗
21. 10.1016/j.tibtech.2011.02.00410.1016/j.tibtech.2011.02.004 ↗
22. 10.1517/1471259100372466210.1517/14712591003724662 ↗
23. U.S. Food and drug administration 2018 United States. (Accessed 2018 March 20).Available from: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm473989.htm (Flaud).
24. European medicines agency 2017 United Kingdom. (Accessed 2018 April 2).Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/001208/WC500049684.pdf (Foclivia).
25. European medicines agency 2017 United Kingdom. (Accessed 2018 April 2).Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/002094/WC500101080.pdf(Aflunov).
26. European medicines agency 2017 United Kingdom. (accessed 2018 April 2).Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2016/02/WC500201798.pdf(Foectoria).
27. European medicines agency 2017 United Kingdom. (Accessed 2018 April 2).Available from: http://www.who.int/immunization_standards/vaccine_quality/Pandemrix_Package_Insert.pdf (Pandemrix).
28. European medicines agency 2017 United Kingdom. (Accessed 2018 April 2).Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000822/WC500041466.pdf/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Summary_for_the_public/human/000822/WC500041467.pdf (Prepandrix).
29. 10.1016/j.vaccine.2010.07.02110.1016/j.vaccine.2010.07.021 ↗
30. 10.1586/14760584.1.1.11110.1586/14760584.1.1.111 ↗
31. 10.1016/j.vaccine.2004.08.04910.1016/j.vaccine.2004.08.049 ↗
32. 10.1016/j.clim.2017.08.00410.1016/j.clim.2017.08.004 ↗
33. 10.1002/eji.20063695910.1002/eji.200636959 ↗
34. 10.18388/abp.2014_187510.18388/abp.2014_1875 ↗
35. 10.3389/fimmu.2018.0034510.3389/fimmu.2018.00345 ↗
36. 10.1016/S1028-4559(08)60004-210.1016/S1028-4559(08)60004-2 ↗
37. 10.1016/j.ygyno.2008.05.03610.1016/j.ygyno.2008.05.036 ↗
38. U.S. Food and drug administration 2018 United States. (Accessed 2018 March 21).Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM110114.pdf (Recombivax).
39. Strategic advisory group of expertson immunization by the hepatitis E vaccine working group from World Health Organization 2014. Geneva Switzerland. (Retrieved 2014 October 1).Available from: http://www.who.int/immunization/sage/meetings/2014/october/2_HepEvaccsafety_immunogenicity_efficacy_final_1Oct2014.pdf (Hepatitis E).
40. U.S. Food and drug administration 2018 United States. (Accessed 2018 April 21). Available from: https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm186981.pdf (Cervarix).
41. U.S. Food and drug administration 2018 United States. (Accessed 2018 April 21). Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf (Gardasil).
42. U.S. Food and drug administration 2018 United States. (Accessed 2018 April 21).Available from: https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm426457.pdf (Gardasil 9).
43. 10.3389/fimmu.2018.0043110.3389/fimmu.2018.00431 ↗
44. 10.1016/S0163-7827(99)00017-X10.1016/S0163-7827(99)00017-X ↗
45. Janssen Pharmaceutical Companies 2018. (Accessed 2018 March31).Available from: http://www.janssen.com/infectious-diseases-and-vaccines/crucell.
46. Electronic Medicines Compendium of UK medicines and healthcare products egulatory agency and the European medicines agency 2018. Accessed 2018 April12).Available from: https://www.medicines.org.uk/emc/product/4035/smpc.
47. European medicines agency 2015. (Accessed 2018 April 8).Available from: https://mri.cts-mrp.eu/Human/Downloads/IT_H_0107_001_FinalPL.pdf.
48. 10.4161/hv.4.4.574210.4161/hv.4.4.5742 ↗
49. 10.3389/fimmu.2018.0015510.3389/fimmu.2018.00155 ↗
50. U.S. Food and drug administration 2018 United States. (Accessed 2018 April 25).Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM581605.pdf (SHINGRIX).
51. 10.1111/apm.1214310.1111/apm.12143 ↗
52. 10.1038/308457a010.1038/308457a0 ↗
53. 10.1177/09564624950060061110.1177/095646249500600611 ↗
54. 10.1016/j.vaccine.2004.05.01310.1016/j.vaccine.2004.05.013 ↗
55. 10.1021/acs.molpharmaceut.6b0043410.1021/acs.molpharmaceut.6b00434 ↗
56. 10.1038/nri262910.1038/nri2629 ↗
57. 10.1056/NEJMoa03059510.1056/NEJMoa030595 ↗
58. 10.4049/jimmunol.172.5.273110.4049/jimmunol.172.5.2731 ↗
59. 10.1371/journal.pone.000986210.1371/journal.pone.0009862 ↗
60. 10.4049/jimmunol.181.5.299010.4049/jimmunol.181.5.2990 ↗